Atossa Therapeutics (NASDAQ:ATOS) Downgraded by StockNews.com to “Sell”

StockNews.com cut shares of Atossa Therapeutics (NASDAQ:ATOS) from a hold rating to a sell rating in a report released on Monday morning.

Other equities research analysts have also issued reports about the stock. Ascendiant Capital Markets increased their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright increased their price target on Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

Atossa Therapeutics Price Performance

ATOS opened at $1.28 on Monday. The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.37. Atossa Therapeutics has a 1 year low of $0.67 and a 1 year high of $2.31. The stock has a market cap of $161.03 million, a P/E ratio of -5.82 and a beta of 1.23.

Institutional Trading of Atossa Therapeutics

Several institutional investors have recently modified their holdings of ATOS. Geode Capital Management LLC increased its stake in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after buying an additional 44,762 shares in the last quarter. Barclays PLC lifted its holdings in Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after purchasing an additional 123,683 shares in the last quarter. XTX Topco Ltd boosted its stake in Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. State Street Corp grew its holdings in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after buying an additional 69,180 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Atossa Therapeutics in the third quarter worth about $75,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.